Godavari Drugs revenue slips to ₹105.81 cr in FY26
The nano-cap pharmaceutical firm reported a modest annual decline in both revenue and profit, though Q4 showed sequential growth.
— 1 earlier story on Godavari Drugs Ltd. →What's new
- FY26 revenue dropped to ₹105.81 cr from ₹113.35 cr in FY25.
- Full-year net profit fell to ₹4.09 cr from ₹4.38 cr.
- Q4 standalone revenue reached ₹33.16 cr, showing sequential and year-on-year improvement.
Why this matters
The results are routine and lack any material surprises. For a nano-cap company, the slight contraction in annual profitability confirms a period of stagnant performance rather than a shift in trajectory.
What we're watching
- Whether Q4's sequential revenue improvement continues into FY27.
- Updates on the use of preferential issue proceeds.
- Any future guidance regarding margin pressures.
The full read
Godavari Drugs closed FY26 with ₹105.81 crore in revenue, a modest decline from the ₹113.35 crore recorded in FY25. Net profit followed a similar path, slipping to ₹4.09 crore from ₹4.38 crore. While the annual figures reflect a slight contraction, the company did report a brighter spot in the final quarter, with standalone revenue hitting ₹33.16 crore. This figure marks both a sequential and year-on-year improvement. Beyond the financials, the filing is strictly procedural, covering standard items like auditor appointments and the upcoming AGM. There were no profit warnings, guidance updates, or unexpected strategic shifts. For investors, this is a routine disclosure that confirms the company's current operational baseline. The numbers contain no surprises.
Questions answered
- How did Godavari Drugs perform in FY26 compared to the previous year?
- The company saw a slight decline in performance, with revenue falling to ₹105.81 crore from ₹113.35 crore and net profit dropping to ₹4.09 crore from ₹4.38 crore.
- Was there any positive momentum in the final quarter?
- Yes, Q4 standalone revenue reached ₹33.16 crore, which represents an improvement on both a sequential and year-on-year basis.
- Did the company announce any major strategic changes?
- No. The filing contains only routine disclosures, such as the appointment of auditors and the scheduling of the AGM.
- Is there any concern regarding the use of capital?
- The company confirmed there was no deviation in the use of proceeds from its preferential issue.
Story so far
All notes on GODAVARI →- 27 May 2026 · 5:02 PM IST Godavari Drugs revenue slips to ₹105.81 cr in FY26
- today Godavari Drugs reports flat FY26 results as revenue slips to ₹105.81 cr